Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2007 1
2008 1
2009 6
2010 7
2011 4
2012 1
2013 3
2014 3
2015 6
2016 8
2017 4
2018 13
2019 15
2020 13
2021 18
2022 11
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L. Lindskrog SV, et al. Among authors: bryan rt. Nat Commun. 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. Nat Commun. 2021. PMID: 33863885 Free PMC article.
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, Chakraborti P, Donovan JL, Elliott PA, French A, Jagdev S, Jenkins B, Keeley FX Jr, Kockelbergh R, Powles T, Wagstaff J, Wilson C, Todd R, Lewis R, Hall E. Birtle A, et al. Among authors: bryan rt. Lancet. 2020 Apr 18;395(10232):1268-1277. doi: 10.1016/S0140-6736(20)30415-3. Epub 2020 Mar 5. Lancet. 2020. PMID: 32145825 Free PMC article. Clinical Trial.
Liquid biopsies for bladder cancer.
Ward DG, Bryan RT. Ward DG, et al. Among authors: bryan rt. Transl Androl Urol. 2017 Apr;6(2):331-335. doi: 10.21037/tau.2017.03.08. Transl Androl Urol. 2017. PMID: 28540249 Free PMC article.
So much cost, such little progress.
Bryan RT, Kirby R, O'Brien T, Mostafid H. Bryan RT, et al. Eur Urol. 2014 Aug;66(2):263-4. doi: 10.1016/j.eururo.2014.02.031. Epub 2014 Feb 22. Eur Urol. 2014. PMID: 24598013 No abstract available.
Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer.
Humayun-Zakaria N, Arnold R, Goel A, Ward D, Savill S, Bryan RT. Humayun-Zakaria N, et al. Among authors: bryan rt. Int J Mol Sci. 2019 Mar 4;20(5):1102. doi: 10.3390/ijms20051102. Int J Mol Sci. 2019. PMID: 30836651 Free PMC article. Review.
Biomarkers in bladder cancer.
Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Bryan RT, et al. BJU Int. 2010 Mar;105(5):608-13. doi: 10.1111/j.1464-410X.2009.08880.x. Epub 2009 Sep 29. BJU Int. 2010. PMID: 19793380 Free article. Review.
Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes.
Goel A, Ward DG, Noyvert B, Yu M, Gordon NS, Abbotts B, Colbourne JK, Kissane S, James ND, Zeegers MP, Cheng KK, Cazier JB, Whalley CM, Beggs AD, Palles C, Arnold R, Bryan RT. Goel A, et al. Among authors: bryan rt. Genome Med. 2022 Jun 3;14(1):59. doi: 10.1186/s13073-022-01056-4. Genome Med. 2022. PMID: 35655252 Free PMC article.
105 results